Fortress Biotech, Inc.
FBIO
$1.81
-$0.02-1.09%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 13.14M | 14.12M | 14.63M | 14.90M | 13.03M |
| Total Other Revenue | -- | 1.00M | -- | -- | -- |
| Total Revenue | 13.14M | 15.12M | 14.63M | 14.90M | 13.03M |
| Cost of Revenue | 8.73M | 12.18M | 14.73M | 19.21M | 30.84M |
| Gross Profit | 4.41M | 2.94M | -102.00K | -4.32M | -17.81M |
| SG&A Expenses | 25.66M | 23.17M | 21.99M | 20.82M | 17.94M |
| Depreciation & Amortization | 1.07M | 3.42M | -- | -- | 814.00K |
| Other Operating Expenses | -- | -4.55M | -- | -- | -- |
| Total Operating Expenses | 35.46M | 34.22M | 36.72M | 40.04M | 49.60M |
| Operating Income | -22.32M | -19.10M | -22.10M | -25.14M | -36.57M |
| Income Before Tax | -24.69M | -25.98M | -26.63M | -28.82M | -39.02M |
| Income Tax Expenses | -- | 336.00K | 69.00K | -- | -- |
| Earnings from Continuing Operations | -24.69M | -26.32M | -26.69M | -28.82M | -39.02M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 14.11M | 19.55M | 13.83M | 17.88M | 23.61M |
| Net Income | -10.58M | -6.77M | -12.87M | -10.95M | -15.42M |
| EBIT | -22.32M | -19.10M | -22.10M | -25.14M | -36.57M |
| EBITDA | -21.13M | -17.98M | -21.14M | -23.95M | -35.38M |
| EPS Basic | -0.48 | -0.37 | -0.76 | -0.73 | -1.04 |
| Normalized Basic EPS | -0.05 | 0.18 | -0.06 | 0.08 | -0.05 |
| EPS Diluted | -0.48 | -0.37 | -0.76 | -0.73 | -1.04 |
| Normalized Diluted EPS | -0.05 | 0.18 | -0.06 | 0.08 | -0.05 |
| Average Basic Shares Outstanding | 26.45M | 26.01M | 19.70M | 18.32M | 17.15M |
| Average Diluted Shares Outstanding | 26.45M | 26.01M | 19.70M | 18.32M | 17.15M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | 0.00% | 0.00% | -18.34% | -13.02% |